nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

02.11.2017 | Original Article – Cancer Research

Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells

verfasst von: Kenichiro Ishii, Izumi Matsuoka, Shinya Kajiwara, Takeshi Sasaki, Manabu Miki, Manabu Kato, Hideki Kanda, Kiminobu Arima, Taizo Shiraishi, Yoshiki Sugimura

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Docetaxel (DTX) is a standard chemotherapeutic drug for castration-resistant prostate cancer (CRPC), although adverse events are common. To overcome this problem, researchers have evaluated the efficacy of DTX treatment in combination with other drugs. Naftopidil is a tubulin-binding drug with fewer adverse events, implying the usefulness of this drug in clinical applications when combined with DTX. Here, we investigated the efficacy of additive naftopidil treatment in combination with DTX on prostate cancer (PCa) cells.

Methods

The effects of combination treatment with DTX plus naftopidil were analyzed using two animal models of LNCaP cells plus PrSC xenografts (sub-renal capsule grafting) and PC-3 xenografts (intratibial injection).

Results

Combination treatment with DTX plus naftopidil significantly inhibited cell growth in LNCaP cells compared with DTX alone. Analysis of the cooperativity index (CI) showed that combination treatment exhibited additive effects on DTX-induced growth inhibition in LNCaP cells. In contrast, combination treatment showed more than an additive (synergistic) effect on DTX-induced apoptosis in LNCaP and PC-3 cells. In LNCaP cells plus PrSC xenografts, combination treatment showed synergistic effects on DTX-induced apoptosis. The synergistic effects of naftopidil on DTX-induced apoptosis were also observed in PC-3 xenografts.

Conclusions

Our results demonstrated that additive naftopidil treatment in combination with DTX increased the efficacy of DTX for the treatment of LNCaP and PC-3 tumors in vivo. Thus, additive naftopidil treatment showed a synergistic effect on DTX-induced apoptosis in PCa cells in vitro and in vivo, suggesting that this treatment approach may yield improved clinical benefits compared with DTX alone.

Dahut WL et al (2013) Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int 111:1269–1280. https://doi.org/10.1111/j.1464-410X.2012.11667.x CrossRefPubMedPubMedCentral

de Bruyn M et al (2010) Melanoma-associated chondroitin sulfate proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 9:301. https://doi.org/10.1186/1476-4598-9-301 CrossRefPubMedPubMedCentral

Dror Michaelson M et al (2009) Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20:913–920. https://doi.org/10.1093/annonc/mdp111 CrossRefPubMedPubMedCentral

Festuccia C et al (2009) Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer 16:401–413. https://doi.org/10.1677/ERC-08-0130 CrossRefPubMed

Fizazi K et al (2013) Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 31:1740–1747. https://doi.org/10.1200/JCO.2012.46.4149 CrossRefPubMed

Harris AM et al (2007) Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 178:2176–2180. https://doi.org/10.1016/j.juro.2007.06.043 CrossRefPubMedPubMedCentral

Heidenreich A et al (2013) A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human alphanu integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann Oncol 24:329–336. https://doi.org/10.1093/annonc/mds505 CrossRefPubMed

Hori Y et al (2011) Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila) 4:87–96. https://doi.org/10.1158/1940-6207.CAPR-10-0189 CrossRef

Ishii K, Sugimura Y (2015) Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: tubulin-binding drug J. Chem Biol 8:5–9. https://doi.org/10.1007/s12154-014-0122-0 CrossRef

Iwamoto Y et al (2013) Oral naftopidil suppresses human renal-cell carcinoma by inducing G(1) cell-cycle arrest in tumor and vascular endothelial cells. Cancer Prev Res (Phila) 6:1000–1006. https://doi.org/10.1158/1940-6207.CAPR-13-0095 CrossRef

Iwamoto Y et al (2017) Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-017-2367-9 PubMed

Izumi K et al (2009) Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. Prostate 69:1222–1234. https://doi.org/10.1002/pros.20975 CrossRefPubMed

Jacks T, Weinberg RA (1996) Cell-cycle control and its watchman. Nature 381:643–644. https://doi.org/10.1038/381643a0 CrossRefPubMed

Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265. https://doi.org/10.1038/nrc1317 CrossRefPubMed

Kanda H, Ishii K, Ogura Y, Imamura T, Kanai M, Arima K, Sugimura Y (2008) Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer 122:444–451. https://doi.org/10.1002/ijc.23095 CrossRefPubMed

Kawabe K (2006) [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia] Yakugaku Zasshi 126 Spec no., pp 199–206

Khasraw M et al (2010) Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol 21:1302–1307. https://doi.org/10.1093/annonc/mdp524 CrossRefPubMed

Kuramoto T et al (2013) Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer. Int J Clin Oncol 18:890–897. https://doi.org/10.1007/s10147-012-0463-z CrossRefPubMed

Li Y, Hong X, Hussain M, Sarkar SH, Li R, Sarkar FH (2005) Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther 4:389–398. https://doi.org/10.1158/1535-7163.MCT-04-0244 PubMed

Mackler NJ, Pienta KJ (2005) Drug insight: use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2:92–100. https://doi.org/10.1038/ncpuro0099 (quiz 101 p following 112)CrossRefPubMed

Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6:229–239. https://doi.org/10.1016/S1470-2045(05)70094-2 CrossRefPubMed

Murtola TJ, Tammela TL, Maattanen L, Ala-Opas M, Stenman UH, Auvinen A (2009) Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer 101:843–848. https://doi.org/10.1038/sj.bjc.6605188 CrossRefPubMedPubMedCentral

Nakai Y et al (2014) Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. Int J Clin Oncol 19:165–172. https://doi.org/10.1007/s10147-013-0536-7 CrossRefPubMed

Ning YM et al (2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:2070–2076. https://doi.org/10.1200/JCO.2009.25.4524 CrossRefPubMedPubMedCentral

Roehrborn CG, Schwinn DA (2004) Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171:1029–1035. https://doi.org/10.1097/01.ju.0000097026.43866.cc CrossRefPubMed

Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R (2017) Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. 10.18632/oncotarget.15303

Sonpavde G et al (2012) Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 23:1803–1808. https://doi.org/10.1093/annonc/mdr555 CrossRefPubMed

Sternberg CN et al (2009) Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 20:1264–1269. https://doi.org/10.1093/annonc/mdn784 CrossRefPubMed

Tsuritani S, Nozaki T, Okumura A, Kimura H, Kazama T (2010) A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. Urol Int 85:80–87. https://doi.org/10.1159/000315994 CrossRefPubMed

Vaishampayan UN et al (2009) Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J Urol 182:317–323. https://doi.org/10.1016/j.juro.2009.02.105 CrossRefPubMed

Yamada D et al (2013) Reduction of prostate cancer incidence by naftopidil, an alpha1 -adrenoceptor antagonist and transforming growth factor-beta signaling inhibitor. Int J Urol 20:1220–1227. https://doi.org/10.1111/iju.12156 CrossRefPubMed

Yokoyama T, Kumon H, Nasu Y, Takamoto H, Watanabe T (2006) Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. Int J Urol 13:932–938. https://doi.org/10.1111/j.1442-2042.2006.01443.x CrossRefPubMed

Yonou H et al (2003) Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 63:2096–2102PubMed

Zhu S, Oremo JA, Li S, Zhen M, Tang Y, Du Y (2014) Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer. PLoS One 9:e91817. https://doi.org/10.1371/journal.pone.0091817 CrossRefPubMedPubMedCentral

Titel: Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells
verfasst von: Kenichiro Ishii
Izumi Matsuoka
Shinya Kajiwara
Takeshi Sasaki
Manabu Miki
Manabu Kato
Hideki Kanda
Kiminobu Arima
Taizo Shiraishi
Yoshiki Sugimura
Publikationsdatum: 02.11.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-017-2536-x

Springer Medizin

Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells